Tecentriq(atezolizumab)
Tecentriq (atezolizumab) is an antibody pharmaceutical. Atezolizumab was first approved as Tecentriq on 2016-05-18. It is used to treat alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small-cell lung carcinoma, and small cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, and urologic neoplasms. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Tecentriq
CombinationsTecentriq hybreza
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tecentriq | Biologic Licensing Application | 2025-11-25 |
| tecentriq hybreza | Biologic Licensing Application | 2025-12-03 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
atezolizumab, Tecentriq, Genentech, Inc. | |||
| 2029-12-09 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9022 | Injection, atezolizumab, 10 mg |
Clinical
Clinical Trials
1670 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | 18 | 21 | 2 | 7 | 50 |
| Neoplasms | D009369 | — | C80 | 15 | 21 | 9 | 1 | 1 | 40 |
| Lung neoplasms | D008175 | — | C34.90 | 6 | 10 | 1 | 1 | 3 | 18 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 17 | 9 | — | 2 | 35 |
| Triple negative breast neoplasms | D064726 | — | — | 6 | 10 | 8 | — | 1 | 24 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 5 | 8 | — | 6 | 19 |
| Small cell lung carcinoma | D055752 | — | — | 4 | 7 | 5 | — | 4 | 18 |
| Carcinoma | D002277 | — | C80.0 | 1 | 8 | 6 | — | 3 | 18 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 6 | 7 | — | 3 | 16 |
| Colorectal neoplasms | D015179 | — | — | 5 | 9 | 3 | — | — | 15 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | 8 | 3 | — | — | 11 |
| Transitional cell carcinoma | D002295 | — | — | 2 | 4 | 2 | — | 3 | 10 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 6 | 1 | — | 1 | 9 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 7 | 5 | — | — | 1 | 9 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 3 | — | — | — | 5 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 4 | — | — | — | 4 |
| B-cell lymphoma | D016393 | — | — | 3 | 2 | — | — | 1 | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 2 | — | — | 1 | 4 |
| Follicular lymphoma | D008224 | — | C82 | 4 | 3 | — | — | — | 4 |
| Leukemia | D007938 | — | C95 | 3 | 1 | — | — | — | 3 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 1 | — | — | — | 3 |
| Sarcoma | D012509 | — | — | — | 3 | — | — | — | 3 |
| Female genital neoplasms | D005833 | — | — | 1 | 2 | — | — | — | 3 |
Show 41 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atezolizumab |
| INN | atezolizumab |
| Description | Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma. It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5XXY:H|heavy chain of atezolizumab fab
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAY
LQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTMDPGGSHHHHHHHH
>5XXY:L|light chain of atezolizumab fab
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 5X8L, 5XXY |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707227 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11595 |
| UNII ID | 52CMI0WC3Y (ChemIDplus, GSRS) |
Target
Agency Approved
CD274
CD274
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Tecentriq – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 42,594 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
32,673 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use